Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Status:
Not yet recruiting
Trial end date:
2026-08-07
Target enrollment:
Participant gender:
Summary
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in
combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary
G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21
patients) will be enrolled (including those enrolled in the safety lead-in portion).